請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32994
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 高照村 | |
dc.contributor.author | Ching-Tzu Yen | en |
dc.contributor.author | 顏靜慈 | zh_TW |
dc.date.accessioned | 2021-06-13T04:21:19Z | - |
dc.date.available | 2008-08-02 | |
dc.date.copyright | 2006-08-02 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-21 | |
dc.identifier.citation | 1. Hokanson JE, Austin MA. Plasma triglyceride level is a ridk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 213-219.
2. Heller DA, de Faire U, Pedersen NL, Dahlen G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 1993; 328: 1150-1156. 3. Murthy V, Julein P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacology & Therapeutics 1996; 70: 101-135. 4. Jong MC, Hofker MH, Havekes LM. Role of ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19: 472-484. 5. Hahn PF. Abolishment of Alimentary Lipemia following injection of heparin. Science 1943; 98: 166-167. 6. Korn ED. Clearing factor, a heparin-activated lipoprotein lipase. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem 1954; 215: 1-14. 7. Krauss RM, Hebert PN, Levy RI, Fredrickson DS. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circulation Res 1973; 33: 403-411. 8. Havel RJ, Gordon Tr. RS. Idiopathic hyperlipidemia: metabolic studies in an affected family. J Clin Invest 1960; 39: 1777-1790. 9. Krauss RM, Windmuller HG, Levy RI, Fredrickson DS. Selective measurement of two different triglyceride lipase activities in rat postheparin plasma. J Lipid Res 1973; 14: 286-295. 10. Breckenridge WC, Little JA, Steiner G, Grow A, Poast M. Hypertriglyceridemia associated with deficiency of apolipoproteins C-II. New Eng J of Med 1978; 298: 1265-1273. 11. Sparkes RS, Zollman S, Klisak I, Kirchgessner TG, Komaromy MC, Mohandas T, Schotz MC, Lusis AJ. Human genes involved in lipolysis plasma lipoproteins: mapping of loci for lipoprotein lipase to 8q22 and heatic lipase to 15q21. Genomics 1987;1: 138144. 12. Deeb SS, Peng RL. Structure of the human lipoprotein lipase gene. Biochemistry 1989; 28: 4131-4135. 13. Wong H, Davis RC, Thuren T, Goers TW, Nikazy J, Waite M, Schotz MC. Lipoprotein lipase domain function. J Biol Chem 1994; 269: 10319-10323. 14. Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J 1992; 287: 337-347. 15. Camps L, Reina M, Liobera M, Vilaro S, Olivercrona T. Lipoprotein lipase: cellular origin and function distribution. American J Phy 1990; 258: c673-681. 16. Bengtsson G, Oliverona T. Interaction of lipoprotein lipase with heparin-sepharose. Evaluation of condition for affinity binding. Biochem J 1997; 109-119. 17. Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N EnglJ Med 1989; 320: 1060-1067. 18. Oliverona T, Bengtsson OG. Lipoprotein lipase from milk: the model in lipoprotein lipase research. In Lipoprotein Lipase 1987; p.15-58. Boernsatajn J, (ed.) Evener Publisher, Inc., Chicago. 19. Kirchgessner TG, Svenson KL, Lusis AJ, Schotz MC. The sequence of cDNA encoding lipoprotein lipase. J Bio Chem 1987; 262: 8463-8466. 20. Wang C-S, Mcconathy J, Kloer HU, Alauovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein CIII. J Clin Invest 1985; 75: 384-390. 21. Mahley RW, Innerarity, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277-1294. 22. Schachter NS. Apolipoprotein C-І and C-Ⅲ as important modulators of lipoprotein metabolism. Curr Opin Lipodol 2001; 12: 297-304. 23. Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med 1978; 298: 1265-1273. 24. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471. 25. Duverger N, Termp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denefle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996; 273: 966-968. 26. Pennacchio LA, Oliver M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rublin EM. An apolipoprotein influencing triglycerides in human and mice revealed by comparative sequencing. Science 2001; 294: 169-173. 27. Pieur X, Coste H, Rodríguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferators-activated receptor-α and contains a novel farnesoid X-activated response element. J Biol Chem 2003; 278: 25468-25480. 28. van der Vliet HN, Sammels MG, Leegwater AV, Levels JH, Reitsma PH, Boers W, Charmuleau RA. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001; 276: 44512-44520. 29. Vu-Dac N, Gervois P, Jakel H, Nowak M, Baugé E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, Fruchart JC. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome-activated receptor α activators. J Biol Chem 2003; 278: 17982-17985. 30. Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodríguez JC. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005; 280: 27533-27543. 31. Genoux A, Dehondt H, Helleboid-Champman A, Duhem C, Hum DW, Martin G, Pennacchio LA, Staels B, Fruchart-Najib J, Fruchart JC. Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORα. Arterioscler Thromb Vasc Biol 2005; 25: 1186-1192. 32. Prieur X, Schaap FG, Coste H, Rodriguez JC. Hepatocyte nuclear factor-4alpha regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-gamma coactivator-1alpha, AMP-activated protein kinase, and mitogen-activated protein kinase pathway. Mol Endocrinol 2005; 19: 3107-3125. 33. Jakel H, Nowak M, Moitort E, Dehondt H, Hum DW, Pennacchio LA, Fruchart-Najib J, Fruchart JC. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 2004; 279: 45462-45469. 34. O’brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005; 51: 351-359. 35. Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, Tsuji M, Ide H, Miller IP, Miller NE, Hattori H. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 2005 ; 46 :2015-22. 36. van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije Norbert, Wesseling JG, Groen AK, Charmuleau RA. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002; 295: 1156-1159. 37. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004; 279: 27941-27947. 38. Huang W, Bi N, Zhang X, Wang Y, Chen B, Liu G. Overexpression of apolipoprotein AV in the liver reduces plasma triglyceride and cholesterol but not HDL in ApoE deficient mice. Biochem Biophys Res Commun. 2006; [Epub ahead of print] 39. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002 ; 11: 3031-3038. 40. Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem 2002; 48: 1597-1600. 41. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11: 3039-3046. 42. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 2002; 111: 570-572. 43. Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, Malloy MJ, Kane JP. Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res. 2003; 44: 1167-1173. 44. Talmud PJ, Palmen J, Putt W, Lins L, Humphries SE. Determination of the functionality of common APOA5 Polymorphisms. J Biol Chem 2005; 280: 28215-28220. 45. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003; 12: 2533-2539. 46. Oliva CP, Pisciotta L, Li volti G, Sambataro MP, Calandra A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2005; 25: 411-417. 47. Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, Ryan RO. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 2003; 278: 34438-34444. 48. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004; 279: 27941-27947. 49. Schaap F, Voshol P, Rensen P, Van der Vliet H, Chamuleau R, Maeda N, Havekes L, Groen A, Willems van Dijk K. Apolipoprotein AV expression ameliorates type III hyperlipidemia in mouse model by stimulating lipoprotein lipase-mediated VLDL-triglyceride hydrolysis. Circulation 2003; 108: 257. Abstract. 50. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA, Fruchart JC. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004; 319: 397-404. 51. Grosskopf I, Baroukh N, Lee SJ, Kamari Y, Harats D, Rubin EM, Pennacchio LA, Cooper AD. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 2005; 25: 2573-2579. 52. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280: 21553-21560. 53. Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 2005; 280: 25383-25387. 54. Feliciello I, Chinali G. A modified alkaline lysis method for the preparation of highly purified DNA from Escherichia Coli. Anal Biochem 1993; 212: 394-401. 55. Joly E. Preparation of plasmid DNA using alkaline lysis. Methods Mol Cell Biol 1996; 58: 257-263. 56. Davanloo P, Rosenberg AH, Dunn JJ, Studier FW. Cloning and expression of the gene for bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 1984; 81: 2035-2039. 57. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 1986; 189: 113-130. 58. Rosenberg AH, Lade BN, Chui DS, Lin SW, Dunn JJ, Studier FW. Vector for selective expression of cloned DNAs by T7 RNA polymerase. Gene 1987; 56: 125-135. 59. Dyke MWV, Sirito M, Sawadogo M. Single-step purification of bacterially expressed polypeptides containing an oligo-histidine domain. Gene 1992; 111: 99-104. 60. Tietz textbook of clinical chemistry. Third edition: 850-851. 61. de Man FH, de Beer F, van der Laarse A, Smelt AH, Havekes LM. Lipolysis of very low density lipoproteins by heparan sulfate proteoglycan-bound lipoprotein lipase. J Lipid Res 1997; 38: 2465-2472. 62. Nomura M. Assembly of bacterial ribosomes. Science 1973; 179: 864-873. 63. Anfinsen CB, Haber E, Sela M, White FH. The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain. Proc Natl Acad Sci U S A 1961; 47: 1309-1314. 64. Ohta Y, Hojo H, Aimoto S, Kobayashi T, Zhu X, Jordan F, Inouye M. Pro-peptide as an intramolecular chaperone: renaturation of denatured subtilisin E with a synthetic pro-peptide. Mol Microbiol 1991; 5: 1507-1510. 65. Hobson AH, Buckley CM, Aamand JL, Jorgensen ST, Diderichsen B, McConnell DJ. Activation of a bacterial lipase by its chaperone. Proc Natl Acad Sci U S A 1993; 90: 5682-4686. 66. Bengtsson G, Olivecrona T. On the pH dependency of lipoprotein lipase activity. Biochim Biophys Acta 1982; 712: 196-199. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32994 | - |
dc.description.abstract | 高三酸甘油脂血症是一種相當常見、致因多樣化的代謝性異常疾病,導因於製造過多、或無法有效清除血液中富含三酸甘油脂的脂蛋白,且高三酸甘油酯血症亦為心血管疾病的一項獨立危險因子。血液中的脂質是由脂蛋白所攜帶以進行代謝;同時,在脂蛋白表面有各式各樣且功能各異的脂蛋白元調節著脂質和脂蛋白的代謝。脂蛋白元AV為近年新發現的一個脂蛋白元,根據先前的研究中指出,在基因改造小鼠體內,血中脂蛋白元AV的含量和三酸甘油脂的濃度成負相關;同時在人類脂蛋白元A5基因的多型性研究中,顯示了許多SNPs與高三酸甘油酯血症具有統計學上的相關性。而近期所發表的研究結果指出脂蛋白元AV能以直接活化或是間接影響的方式來提升脂蛋白解脂酶的水解能力,藉此降低血液中的三酸甘油酯。
本實驗室所發現的c.553G>T多型性,會造成脂蛋白元AV的第185個胺基酸由甘胺酸(glycine)變為半胱胺酸(cysteine),為瞭解此變異型脂蛋白元AV影響三酸甘油酯正常代謝之機制,在本篇論文中,建構了此變異型之質體,利用細菌表現、並純化出重組脂蛋白元AV。在體外脂蛋白解脂酶活性分析中,野生型和變異型脂蛋白元AV皆能提升脂蛋白解脂酶的活性,但後者的能力較差(較野生型降低26%, p<0.001)。只是這樣的實驗結果在以其他批次純化的重組脂蛋白元AV進行分析時,無法重複呈現;同時,也發現到實驗結果會受到尿素濃度、溫度以及脂蛋白元AV活性的穩定度等其他因子的影響。此外,為模擬生理環境,更進一步將脂蛋白解脂酶連結在HSPG上進行活性分析,雖然兩者皆能促進HSPG連結脂蛋白解脂酶的水解能力,但彼此之間並無統計學上的差異。 目前實驗的結果,仍無法證明變異型脂蛋白元AV影響三酸甘油酯代謝的機轉,未來若能以apoa5基因剔除小鼠為動物模式做更進一步的探討,將能給予更多的解答。 | zh_TW |
dc.description.abstract | Hypertriglyceridemia(HTG)is a common metabolic disorder resulted from multiple determinants. It may arise from either over-production or defective clearance of triglyceride-rich lipoproteins in circulation. Furthermore, HTG is also an independent risk factor for coronary heart disease. Plasma lipid is known to be carried by lipoproteins and to undergo further hydrolysis. Meanwhile, diverse-functioned apolipoproteins on lipoproteins modulate metabolism of lipid and lipoprotein. ApoAV was discovered as a new member of the apolipoprotein. Early studies indicated that the concentration of apoAV exerted an inverse correlation with the level of plasma triglyceride(TG)in genetically engineered mice. The studies also revealed that the APOA5 gene polymorphism in human was statistically correlated with the incidence of HTG. Recently studies have shown that apoAV can modulate the triacylglycerol hydrolase activity of lipoprotein lipase(LPL)through direct activation or indirect effects to reduce the plasma TG.
We have identified a c.553G>T polymorphism, resulting in the substitution of cysteine for glycine at residue 185. To gain insight into the mechanism of the effect of APOA5 185C variant, we constructed the vector carrying APOA5 185C variant cDNA, and then expressed and purified the recombinant apoAV. Using in vitro LPL activity assay, we initially showed that both apoAV wild type and 185C variant significantly increased LPL activity, but the later was less effective(26% lower compared to apoAV wild type. p<0.001). But this result could not be reproduced using recombinant apoAV purified at different batch. Meanwhile, we also found other factors, such as urea, temperature and the stability of apoAV activity, would cause variation of results. Furthermore, in order to reflect the physiological situation in which LPL is bound to cell surface through HSPG, we examined the effect of apoAV on the LPL activity in the presence of HSPG. Although both wild type and variant significantly increased lipolysis ability of HSPG-bound LPL, there was no statistical difference between them. According to results of this study, the mechanism of the effect of APOA5 185C variant on triglyceride metabolism remains uncertain. Further animal studies using apoa5 knockout mice will be necessary in order to explore the mechanism in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:21:19Z (GMT). No. of bitstreams: 1 ntu-95-R93424010-1.pdf: 847397 bytes, checksum: 43d1b6a92f44043dcb1976e44f10df15 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 總目次
總目次.…………………………………………………………………..…….Ⅰ 圖目次……………………………………………………………………..…..Ⅲ 表目次……………………………………………………………….……..….Ⅳ 簡稱或縮寫對照表…………………………………………………………....Ⅴ 摘要……………………………………………………………………………Ⅷ Abstract……………………………………………………………………..…Ⅸ 第一章 導論 第一節 前言…………………………………………………………..…1 第二節 高三酸甘油酯血症…………………………………………..…1 第三節 脂蛋白解脂酶………………………………………………..…1 第四節 脂蛋白元……………………………………………………..…3 第五節 脂蛋白元AV…………………………………………………....4 第六節 研究動機………………………………………………………..8 第二章 實驗材料與方法 第一節 儀器設備………………………………………………………..9 第二節 試藥、試劑組與耗材…………………………………………..10 第三節 實驗方法………………………………………………………13 第三章 實驗結果 第一節 變異型脂蛋白元A5(pET-a5185C)的選殖…………………..20 第二節 重組脂蛋白元AV的表現、純化、及確認…………………..20 第三節 極低密度脂蛋白的分離………………………………………21 第四節 試管內脂蛋白解脂酶活性分析………………………………22 第五節 96微滴孔盤內脂蛋白解脂酶活性分析………………...........23 第六節 野生型重組脂蛋白元AV活性穩定度分析……………….....24 第四章 討論…………………………………………………………………..25 附圖……………………………………………………………………………31 附表……………………………………………………………………………46 附錄實驗流程…………………………………………………………………49 參考文獻………………………………………………………………………66 | |
dc.language.iso | zh-TW | |
dc.title | 變異型脂蛋白元AV功能之研究 | zh_TW |
dc.title | Functional Study of Apolipoprotein AV Variant | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林淑華,江福田 | |
dc.subject.keyword | 脂蛋白元AV, | zh_TW |
dc.subject.keyword | apolipoprotein AV, | en |
dc.relation.page | 72 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 827.54 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。